Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27271595 | 0.81 | DYRK1A (0.34) | DYRK1AHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14895067 | 0.81 | DYRK1A (0.39) | DYRK1AHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21403547 | 0.81 | HTT (0.37) | DYRK1AHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31354048 | 0.78 | HTT (0.33) | DYRK1AHTTKMT2APTGES | |
| SCHEMBL21403557 | 0.78 | DYRK1A (0.32) | DYRK1ANQO2 | |
| SCHEMBL15566402 | 0.77 | CCR1 (0.45) | — | |
| SCHEMBL18109358 | 0.77 | TLR8 (0.33) | — | |
| SCHEMBL4978434 | 0.74 | DYRK1A (0.37) | DYRK1AHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14895071 | 0.73 | DYRK1A (0.42) | DYRK1AALDH1A1 | |
| SCHEMBL29487338 | 0.71 | MPO (0.41) | DYRK1AHTTPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276968-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250250286-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA INC (US) | 2025-08-07 | — | — | US | disclosed |
| CN-119156387-A | 8-Substituted and 6-substituted pyridopyrimidine derivatives as KRAS inhibitors | 贝达医药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118339146-A | Fused pyrimidine derivatives as KRAS oncoprotein inhibitors | 贝达医药公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240140948-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2023219941-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648452-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250286-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 3530/4885HTT 3671/4885SMN1; SMN2 2604/4885 |
| US-20250276968-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 3278/4885HTT 4171/4885SMN1; SMN2 1571/4885 |
| US-20240140948-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 3423/4885HTT 3842/4885SMN1; SMN2 1839/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | DYRK1A 166/4885HTT 2875/4885SMN1; SMN2 1256/4885 |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | DYRK1A 166/4885HTT 2875/4885SMN1; SMN2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.